Localized BCNU chemotherapy and the multimodal management of malignant glioma

Initial Experience Involving Treatment and Retreatment With Carmustine Wafers in Combination With Oral Temozolomide: Long-term Survival in a Child With Relapsed Glioblastoma Multiforme

“…Thus, the therapeutic strategy proposed for our patient was similar to that described by Gururangan, in more recent publications 23 focused on treatment of GBM in adults (ie, the combination of local carmustine and oral temozolomide following maximal resection), and based on our own management of older patients. 23,27 This combination clearly seems to offer benefits without significant sequelae, at least for patients suited for gross macroscopic excision (ie, those with good Karnofsky status scores, and of young age) in whom long-term survival has been achieved with a high safety profile. 7,23 For patients with relapsed or progressive disease the options are limited.…”

Upregulation of tumor suppressor WWOX promotes immune response in glioma

“…The most malignant glial neoplasm is glioblastoma multiforme (GBM), which is associated with a low 5-year survival rate [28][29][30]. Because improvements in conventional treatment modalities have had only a modest impact on survival, experimental therapies such as immunotherapy are being considered.…”

Subcutaneous malignant melanoma of the scalp surgical flap after brain irradiation for anaplastic astrocytoma

“…Radio-chemotherapy is a standard adjuvant treatment for malignant brain gliomas (BGs) [1][2][3][4][5][6][7], although arteritis, radionecrosis, leukoencephalopathy, and secondary malignant tumours (SMTs) originating from surrounding tissues, which inevitably absorb ionizing radiation (IR), are possible late effects [8][9][10][11][12][13][14].…”